Science-to-Company Cross-Pollination
Pair scientific breakthroughs with builders who can commercialize them
- Difficulty
- Expert
- Time to result
- ~ongoing to results
- Steps
- 6
- Confidence
- 92%
Armstrong argues that scientists and entrepreneurs often occupy separate worlds: research can remain siloed and uncommercialized, while many businesses lack meaningful scientific foundations. The highest-value opportunity appears where a true scientific innovation meets someone able to build and distribute a company around it. The bridge requires people who can understand enough of both languages to translate capabilities, constraints, and incentives. Examples he names include Genentech, SpaceX, Google, and Coinbase, the last of which grew from the Bitcoin research paper. The mechanism is a cross-pollination loop: identify a technical breakthrough, connect scientists with builders, turn it into a practical product, and use the resulting economic value to support more innovation.
Origin
Armstrong describes this model while explaining why he studies biology and funds NewLimit and ResearchHub alongside his work at Coinbase.
Core principles
- 01Scientific discovery and entrepreneurship often live in separate communities
- 02A breakthrough creates broad value only when it becomes usable
- 03Translators who understand both domains can connect discovery to markets
- 04Commercialization can fund further scientific progress
How to run it
- 1
Start with real science
Find a defensible discovery or technical capability with the potential to solve an important problem. Verify that the innovation is more than marketing language.
Pro tip Trace the opportunity to the paper, tool, or experimental result.
Watch out Do not manufacture a scientific story around an ordinary product.
- 2
Define the human use
Translate the capability into a concrete outcome for people, institutions, or infrastructure. Identify who benefits and what becomes newly possible.
Pro tip Use a specific functional milestone before a moonshot claim.
Watch out A breakthrough without a usable target can remain a research curiosity.
- 3
Connect both worlds
Bring scientists, technical operators, investors, and entrepreneurs into direct conversation. Use translators who can understand enough of each side to prevent false assumptions.
Pro tip Create recurring forums rather than a single introduction.
Watch out Neither domain should treat the other as merely a service provider.
- 4
Form a product thesis
Choose an initial application that can be tested and commercialized while advancing the larger scientific goal. Define intermediate milestones that produce evidence.
Pro tip Let a narrow application de-risk the wider platform.
Watch out Do not wait for the full moonshot before testing value.
- 5
Build the company bridge
Create the team, capital structure, tools, and distribution needed to move from research to a repeatable offering. Keep scientific and commercial feedback connected.
Pro tip Hire for both experimental rigor and operational execution.
Watch out Commercial pressure must not override research integrity.
- 6
Reinvest the gains
Use new data, tools, talent, and financial returns to expand the science and pursue harder applications. Make commercialization a compounding input to discovery.
Pro tip Design the company so product use can improve the research loop.
Watch out Do not let short-term revenue permanently narrow the scientific mission.
In the wild
Armstrong points to Coinbase as a company rooted in a research paper rather than a marketing-only concept. Bitcoin supplied the technical breakthrough; Coinbase built trusted, easier-to-use products that helped people and institutions access the resulting financial system.
→ A research innovation became usable infrastructure and a large commercial company.
After hosting dinners with biotech experts, scientists, CEOs, and investors, Armstrong focused on epigenetic reprogramming. He partnered with scientist and biotech investor Blake Byers to fund NewLimit, which tests transcription factors across cell types with machine learning and pursues functional rejuvenation milestones.
→ A scientific possibility became a funded company with a platform and intermediate therapeutic targets.
Common mistakes
Keeping disciplines siloed
Scientists may miss distribution and incentives while entrepreneurs miss the technical substance needed for a breakthrough company.
Starting with commercialization theater
A marketing concept dressed in scientific language lacks the real innovation this model requires.
Skipping intermediate milestones
A moonshot without narrower functional targets cannot generate evidence or guide execution.
Is it for you?
Best for
Deep-tech opportunities where real research exists but scientists and commercial operators lack a shared bridge.
Not ideal for
Marketing-led products that claim scientific novelty without a genuine technical breakthrough.
From the transcript
“most scientists are building things which never get commercialized”
“the most valuable companies in the world are when we cross-pollinate a true scientific innovation with someone who can go commercialize it”
“the few people in the world who can speak both languages like a translator they they know enough business to be dangerous and enough science…”
From the episode
#627: Brian Armstrong, CEO of Coinbase — The Art of Relentless Focus, Preparing for Full-Contact Entrepreneurship, Critical Forks in the Path, Handling Haters, The Wisdom of Paul Graham, Epigenetic Reprogramming, and Much More
Brian Armstrong